23Andme Holding Co. - notizie pubblicate 216 - letture 5.283


23Andme Holding Co.

23ANDME HOLDING CO.

23andMe Reports FY2023 Third Quarter Financial Results - Form 8-K

The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer 23andme holding co. ...

08.02.2023
23Andme Holding Co.

23ANDME HOLDING CO.

Sales Agreement - Form 8-K

8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...

07.02.2023
23Andme Holding Co.

23ANDME HOLDING CO.

23andMe to Report FY2023 Third Quarter Financial Results

23andme to report fy2023 third quarter financial results january 26, 2023 south san francisco, calif., jan. 26, 2023 (globe newswire) -- 23andme holding co. (nasdaq: me) (23andme), ...

26.01.2023
23Andme Holding Co.

23ANDME HOLDING CO.

Management Change - Form 8-K

8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 15(d) of the securities exchange act of 1934 date of repo ...

09.12.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

06.12.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

22.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

22.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

22.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Statement of Changes in Beneficial Ownership - Form 4

Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...

14.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Notice of Effectiveness - Form EFFECT

Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: november 8, 2022 accession number: 00011 ...

09.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Supplemental Prospectus - Form 424B3

424b3 filed pursuant to rule 424(b)(3) registration statement no. 333-257768 prospectus supplement no. 17 (to prospectus dated july 15, 2021) 23andme holding co. 280,940,853 shares ...

07.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

Quarterly Report for Quarter Ending September 30, 2022 (Form 10-Q)

10-q table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☑ quarterly report pursuant to section 13 or 15(d) of the secu ...

07.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

23andMe Reports FY2023 Second Quarter Financial Results - Form 8-K

23andme reports fy2023 second quarter financial results second quarter revenue grew 37% to $76 million consumer revenue grew 27% year over year due to the addition of telehealth re ...

07.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

23andMe Reports FY2023 Second Quarter Financial Results

23andme reports fy2023 second quarter financial results november 7, 2022 second quarter revenue grew 37% to $76 million consumer revenue grew 27% year over year due to the addition ...

07.11.2022
23Andme Holding Co.

23ANDME HOLDING CO.

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

23andme trials-in-progress poster details expansion cohorts for 23me-00610, an investigational antibody targeting cd200r1, at the society for immunotherapy of cancer's (sitc) 2022 ...

07.11.2022
Condividi